This synergistic rationale drove the two-part structure of Toragen’s Phase 1 trial, with monotherapy in Part 1 and ...

EU CHMP recommends approval of Merck’s Keytruda plus Padcev as perioperative treatment for adults with cisplatin-ineligible resectable muscle-invasive bladder cancer: Rahway, Ne ...

All of them could be "forever" holdings, but the coming decade could prove surprisingly fruitful for each of these outfits.

Korea approves Keytruda SC, slashing treatment time to 2 minutes Alteogens ALT-B4 enables faster subcutaneous Keytruda launch ...

Go behind the scenes of the Cancer Calculus investigation, and hear insights about Merck's cancer drug Keytruda from ICIJ's ...

Read all the latest news headline updates on cancer drugs. Get all the cancer drugs breaking news updates, videos, photostories and more at Business Standard.

Merck stock popped early Friday after European officials recommended approving its combination for a form of bladder cancer.

BioInvent International (STO:BINV)24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by ...

BioInvent International (STO:BINV)24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by ...

Detailed price information for Regeneron Pharmaceuticals (REGN-Q) from The Globe and Mail including charting and trades.

Though the Tecentriq SC has created buzz, oncologists say it is not about speed. It reflects how cancer care is evolving from ...

BioOrbit hopes drug-crystallisation technology will lead to self-injected cancer treatment that could save millions ...